Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MIF | P14174 | 10/20 | 1.00 |
| ▸ | NPC1 | O15118 | 5/20 | 1.00 |
| ▸ | RAB9A | P51151 | 4/20 | 1.00 |
| ▸ | MEN1 | O00255 | 3/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 3/20 | 1.00 |
| ▸ | ERAP1 | Q9NZ08 | 2/20 | 1.00 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 1.00 |
| ▸ | SIRT3 | Q9NTG7 | 1/20 | 1.00 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.76 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.72 |
| ▸ | ATM | Q13315 | 1/20 | 0.72 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.72 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.68 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.68 |
| ▸ | GLA | P06280 | 1/20 | 0.68 |
| ▸ | POLB | P06746 | 1/20 | 0.68 |
| ▸ | GAA | P10253 | 1/20 | 0.68 |
| ▸ | HPGD | P15428 | 1/20 | 0.68 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.68 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29402681 | 1.00 | MIF (1.00) | MIFNPC1RAB9AMEN1KMT2A | |
| SCHEMBL28843685 | 0.89 | MIF (0.80) | MIFNPC1RAB9AMEN1KMT2A | |
| SCHEMBL7116819 | 0.88 | NPC1 (0.83) | MIFNPC1RAB9AMEN1KMT2A | |
| SCHEMBL2166723 | 0.87 | ESR2 (1.00) | MIFNPC1RAB9AMEN1KMT2A | |
| SCHEMBL28596131 | 0.85 | MIF (1.00) | MIFNPC1RAB9AMEN1KMT2A | |
| SCHEMBL30108442 | 0.85 | MIF (1.00) | MIFNPC1RAB9AMEN1KMT2A | |
| SCHEMBL11083775 | 0.84 | NPC1 (0.73) | MIFNPC1RAB9AMEN1KMT2A | |
| SCHEMBL10453916 | 0.84 | MAOB (0.80) | MIFNPC1RAB9AMEN1KMT2A | |
| SCHEMBL5082383 | 0.84 | NPC1 (1.00) | MIFNPC1RAB9AMEN1KMT2A | |
| SCHEMBL5940810 | 0.84 | MIF (0.71) | MIFNPC1RAB9AMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 80 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220290155-A1 | A Method Of Promoting Survival And/Or Function Of A Motor Neuron And Related Agents, Uses And Methods | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2022-09-15 | — | — | US | claimed |
| EP-4021448-A1 | A METHOD OF PROMOTING SURVIVAL AND/OR FUNCTION OF A MOTOR NEURON AND RELATED AGENTS, USES AND METHODS | Agency for Science, Technology and Research (SG) | 2022-07-06 | — | — | EP | claimed |
| CN-114173783-A | Methods of promoting survival and/or function of motor neurons and related agents, uses and methods | 新加坡科技研究局 | 2022-03-11 | — | — | CN | claimed |
| CN-113121485-A | 3-aryl coumarin derivative and preparation method and application thereof | 中山大学 | 2021-07-16 | — | — | CN | claimed |
| WO-2021040627-A1 | A METHOD OF PROMOTING SURVIVAL AND/OR FUNCTION OF A MOTOR NEURON AND RELATED AGENTS, USES AND METHODS | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2021-03-04 | — | — | WO | claimed |
| EP-2575447-B1 | LIQUID COMPOSITIONS COMPRISING A SUSTAINED RELEASE SYSTEM FOR INSECTICIDES | EXOSECT LTD (GB) | 2015-07-01 | — | — | EP | claimed |
| WO-2009118338-A2 | USE OF A POLYPHENOLIC TYPE COMPOUND FOR PREVENTING OR TREATING A POLYGLUTAMINE EXPANSION NEURODEGENERATIVE DISEASE | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2009-10-01 | — | — | WO | claimed |
| CN-101386612-A | Compounds with 3-phenyl-7-hydroxyl tonka bean camphor structure and medicinal use thereof | UNIV FUDAN (CN) | 2009-03-18 | — | — | CN | claimed |
| JP-2003504327-A | — | — | 2003-02-04 | — | — | JP | claimed |
| EP-1223928-A2 | USE OF FLAVONES, COUMARINS AND RELATED COMPOUNDS TO TREAT INFECTIONS | Prendergast, Patrick Thomas (IE) | 2002-07-24 | — | — | EP | claimed |
| WO-2001003681-A2 | USE OF FLAVONES, COUMARINS AND RELATED COMPOUNDS TO TREAT INFECTIONS | PRENDERGAST PATRICK T (IE) | 2001-01-18 | — | — | WO | claimed |
| EP-2879490-B1 | CONTROL OF ARTHROPOD INFESTATION | TERRAMERA EXCO HOLDINGS LTD (CA) | 2026-04-01 | — | — | EP | disclosed |
| EP-2557922-B1 | CONTROL OF ARTHROPODS IN ANIMAL ENVIRONMENTS | TERRAMERA EXCO HOLDINGS LTD (CA) | 2024-06-26 | — | — | EP | disclosed |
| US-20240156973-A1 | OSTEOTROPIC COMPOSITIONS AND USES THEREOF | PURDUE RESEARCH FOUNDATION | 2024-05-16 | — | — | US | disclosed |
| EP-4340890-A1 | OSTEOTROPIC COMPOSITIONS AND USES THEREOF | Purdue Research Foundation (US) | 2024-03-27 | — | — | EP | disclosed |
| WO-2007115181-A2 | COMPOUNDS EXHIBITING EFFLUX INHIBITOR ACTIVITY AND COMPOSITIONS AND USES THEREOF | EASTMAN CHEMICAL COMPANY (US) | 2007-10-11 | — | — | WO | disclosed |
| WO-2007089878-A2 | SUTURES AND ANTI-SCARRING AGENTS | ANGIOTECH PHARMACEUTICALS, INC. (CA) | 2007-08-09 | — | — | WO | disclosed |
| US-6555523-B1 | Such as 3',4'-diacetoxy-5,6,7-trimethoxyflavone or naringin in the treatment HIV, picornavirus, and/or respiratory virus | CASCADE ESTATES LTD. (MU) | 2003-04-29 | — | — | US | disclosed |
| EP-1223928-A2 | USE OF FLAVONES, COUMARINS AND RELATED COMPOUNDS TO TREAT INFECTIONS | Prendergast, Patrick Thomas (IE) | 2002-07-24 | — | — | EP | disclosed |
| WO-2001003681-A2 | USE OF FLAVONES, COUMARINS AND RELATED COMPOUNDS TO TREAT INFECTIONS | PRENDERGAST PATRICK T (IE) | 2001-01-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220290155-A1 | A Method Of Promoting Survival And/Or Function Of A Motor Neuron And Related Agents, Uses And Methods | SMN1; SMN2, MORF4L1, NLN | MIF 2580/4885NPC1 1858/4885RAB9A 3702/4885 |
| US-20240156973-A1 | OSTEOTROPIC COMPOSITIONS AND USES THEREOF | SOST, BMP2, BMP6 | MIF 2266/4885NPC1 414/4885RAB9A 321/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.